Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2005 1
2008 1
2009 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Electromotive administration of oxybutynin into the human bladder wall.
Di Stasi SM, Giannantoni A, Massoud R, Cortese C, Vespasiani G, Micali F. Di Stasi SM, et al. J Urol. 1997 Jul;158(1):228-33. doi: 10.1097/00005392-199707000-00076. J Urol. 1997. PMID: 9186365
PURPOSE: To compare concentrations of oxybutynin in the human bladder wall after either passive delivery (PD) or electromotive administration (EMDA). ...Oxybutynin tissue contents were measured and tissue viability, morphology and oxybutynin stability …
PURPOSE: To compare concentrations of oxybutynin in the human bladder wall after either passive delivery (PD) or electromotive …
Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, Guvel S, Ozkardes H. Altan-Yaycioglu R, et al. Br J Clin Pharmacol. 2005 May;59(5):588-92. doi: 10.1111/j.1365-2125.2005.02356.x. Br J Clin Pharmacol. 2005. PMID: 15842558 Free PMC article. Clinical Trial.
AIM: To evaluate the effects of tolterodine and oxybutynin on visual accommodation, pupillary diameter, intraocular pressure and tear secretion in women with overactive bladder. ...At day 28, PD in dim light was significantly larger in the tolterodine treated group …
AIM: To evaluate the effects of tolterodine and oxybutynin on visual accommodation, pupillary diameter, intraocular pressure and tear …
Treatment of dysautonomia associated with Parkinson's disease.
Mostile G, Jankovic J. Mostile G, et al. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S224-32. doi: 10.1016/S1353-8020(09)70820-X. Parkinsonism Relat Disord. 2009. PMID: 20082997
Non-motor symptoms are increasingly recognized to adversely impact on the quality of life of patients with in Parkinson's disease (PD), particularly as the disease progresses. Autonomic symptom severity in patients with PD seems to correlate with older age, greater …
Non-motor symptoms are increasingly recognized to adversely impact on the quality of life of patients with in Parkinson's disease (PD …
Semiparametric mixed-effects analysis of PK/PD models using differential equations.
Wang Y, Eskridge KM, Zhang S. Wang Y, et al. J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):443-63. doi: 10.1007/s10928-008-9096-2. Epub 2008 Sep 10. J Pharmacokinet Pharmacodyn. 2008. PMID: 18781382
Motivated by the use of semiparametric nonlinear mixed-effects modeling on longitudinal data, we develop a new semiparametric modeling approach to address potential structural model misspecification for population pharmacokinetic/pharmacodynamic (PK/PD) analysis. Specifica …
Motivated by the use of semiparametric nonlinear mixed-effects modeling on longitudinal data, we develop a new semiparametric modeling appro …
Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle.
Choppin A, Eglen RM. Choppin A, et al. Br J Pharmacol. 2001 Feb;132(4):835-42. doi: 10.1038/sj.bjp.0703901. Br J Pharmacol. 2001. PMID: 11181424 Free PMC article.
These responses were antagonized by several muscarinic receptor antagonists (pKb values for the ciliary muscle and the bladder smooth muscle, respectively): atropine (8.25+/-0.14 and 9.21+/-0.09), pirenzepine (6.31+/-0.13 and 6.70+/-0.25), tolterodine (7.97+/-0.14 and 8.68+/-0.12 …
These responses were antagonized by several muscarinic receptor antagonists (pKb values for the ciliary muscle and the bladder smooth muscle …